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Abstract	  	  26 
2,4-­‐Dinitrophenol	  (DNP),	  a	  molecule	  uncoupling	  mitochondrial	  oxidative	  phosphorylation	  from	  oxygen	  27 
consumption,	  is	  illegally	  used	  by	  humans	  as	  a	  diet	  pill,	  but	  is	  nonetheless	  investigated	  as	  a	  potential	  28 
human	  medicine	  against	  ‘metabesity’.	  Due	  to	  its	  proven	  acute	  toxicity	  and	  the	  scarceness	  of	  long-­‐term	  29 
studies	  on	  DNP	  administration	  in	  vertebrates,	  we	  determined	  the	  impact	  of	  a	  long-­‐term	  DNP	  treatment	  30 
(~4	  mg.kg-­‐1.day-­‐1,	  i.e.	  within	  the	  range	  taken	  illegally	  by	  humans)	  on	  body	  mass,	  metabolism,	  ageing	  31 
and	  lifespan	  in	  a	  captive	  bird	  model,	  the	  zebra	  finch.	  The	  chronic	  absorption	  of	  DNP	  over	  life	  (>4	  years)	  32 
led	   to	   a	   mild	   increase	   in	   energy	   expenditure	   (ca.	   +11%	   compared	   to	   control	   group),	   without	  33 
significantly	   altering	   the	   normal	   slight	   increase	   in	   body	   mass	   with	   age.	   DNP	   did	   not	   significantly	  34 
influence	   the	   alteration	   of	   physical	   performance,	   the	   rise	   in	   oxidative	   damage,	   or	   the	   progressive	  35 
shortening	   of	   telomeres	   with	   age.	   However,	   DNP-­‐treated	   individuals	   had	   a	   significantly	   shorter	  36 
lifespan	  (ca.	  -­‐21%	  in	  median	  lifespan	  compared	  to	  control	  group),	  thereby	  raising	  potential	  concerns	  37 
about	  DNP	  use	  as	  a	  diet	  pill	  or	  medicine.	   	  38 
Introduction	  39 
There	  is	  much	  public	  and	  academic	  interest	  in	  discovering	  human	  nutritional	  supplements	  that	  40 
increase	  fat	  metabolism	  and	  so	  promote	  body	  mass	  loss	  (Jeukendrup	  and	  Randell,	  2011).	  One	  example	  41 
of	  those	  substances	  is	  2,4-­‐Dinitrophenol	  (DNP),	  an	  industrial	  product	  that	  was	  found	  to	  trigger	  body	  42 
mass	  loss	  when	  accidently	  inhaled	  by	  factory	  workers	  in	  the	  1930s	  (Harris	  and	  Cocoran,	  1995).	  Early	  43 
scientific	  studies	  established	  that	  DNP	  is	  an	  efficient	  means	  to	  promote	  body	  mass	  loss,	  but	  its	  acute	  44 
toxicity	  was	  quickly	  revealed,	  culminating	  in	  many	  fatalities	  and	  the	  prohibition	  of	  its	  usage	  as	  human	  45 
medicine	   (Harris	   and	   Cocoran,	   1995).	   However,	   DNP	   made	   its	   comeback	   in	   recent	   years,	   being	  46 
marketed	  and	  sold	  illegally	  through	  the	  internet	  and	  social	  media	  (Ainsworth	  et	  al.,	  2018;	  McVeigh	  et	  47 
al.,	  2017).	  This	  led	  to	  a	  marked	  increase	  in	  DNP	  usage	  and	  its	  associated	  risks,	  culminating	  in	  several	  48 
fatalities	  per	  year	  in	  the	  last	  decade	  (Grundlingh	  et	  al.,	  2011;	  Hoxha	  and	  Petroczi,	  2015).	  49 
DNP	  promotes	  body	  mass	  loss	  through	  a	  partial	  uncoupling	  of	  the	  oxidative	  phosphorylation	  50 
(ATP	  production)	  system	  in	  mitochondria	  (Harris	  and	  Cocoran,	  1995).	  When	  uncoupled,	  mitochondria	  51 
are	   less	   efficient	   in	   converting	   energy	   and	  use	  more	   fuel	   to	   provide	   an	   equivalent	   amount	   of	  ATP	  52 
(Brand,	   2000).	   Concomitantly,	  mild	  mitochondrial	   uncoupling	   has	   the	   potential	   to	   reduce	   reactive	  53 
oxygen	   species	   (ROS)	  production	  by	   the	  mitochondria,	   and	   thus	   to	  prevent	  oxidative	   stress	  and	   to	  54 
extend	   lifespan	  according	  to	  the	  uncoupling	  to	  survive	  hypothesis	   (Brand,	  2000).	  Experiments	  using	  55 
DNP	  in	  various	  eukaryotic	  models	  (see	  Table	  1)	  mostly	  support	  the	  uncoupling	  to	  survive	  hypothesis.	  56 
However,	  DNP	  induces	  mitochondrial	  heat	  production,	  thereby	  making	  results	  from	  ectotherms	  (Table	  57 
1)	   potentially	   difficult	   to	   translate	   to	   endotherms,	   including	   humans.	   Additionally,	   the	   beneficial	  58 
effects	  observed	  in	  mice	  (i.e.	  increased	  longevity,	  improved	  glucose-­‐insulin-­‐triglycerides	  plasma	  levels,	  59 
decreased	  oxidative	   stress	   levels;	   Caldeira	  da	   Silva	  et	   al.,	   2008)	  might	  be	  associated	  with	   the	  anti-­‐60 
obesity	  effect	  of	  DNP	  in	  this	  species.	  Such	  beneficial	  effects	  might	  thus	  be	  absent	  in	  animal	  models	  not	  61 
displaying	  age-­‐related	  obesity	  or	  in	  non-­‐obese	  humans.	  Despite	  its	  known	  toxicity	  (Harris	  and	  Cocoran,	  62 
1995),	  DNP	  has	  recently	  been	  granted	  an	  open	  Investigation	  New	  Drug	  (IND)	  approval	  by	  the	  FDA	  to	  63 
begin	  clinical	  testing	  linked	  to	  its	  potential	  to	  prevent	  ‘metabesity’	  (i.e.	  global	  comorbidities	  associated	  64 
with	   the	   over-­‐nutritional	   phenotype;	   Geisler,	   2019).	   Therefore,	   it	   seems	   timely	   to	   evaluate	   the	  65 
potential	   effects	   of	   chronic	   DNP	   treatment	   on	   ageing	   and	   lifespan	   using	   endotherm	   models	   not	  66 
displaying	  age-­‐related	  obesity.	  67 
We	  previously	  highlighted	  that	  medium-­‐term	  (i.e.	  1	  month)	  DNP	  chronic	  treatment	  at	  a	  dose	  68 
of	   ~4	   mg.kg-­‐1.day-­‐1	   (i.e.	   within	   the	   range	   taken	   illegally	   by	   humans;	   Table	   1)	   had	   the	   expected	  69 
stimulating	  effect	  on	  metabolic	   rate	   in	  captive	  zebra	   finches	   (Taeniopigya	  guttata),	  but	  was	  mainly	  70 
compensated	  by	  a	  corresponding	  increase	  in	  food	  intake	  (Stier	  et	  al.,	  2014).	  In	  the	  present	  article,	  we	  71 
use	   long-­‐term	   data	   collected	   on	   the	   same	   birds	   to	   test	   the	   effects	   of	   DNP	   on	   lifelong	   body	  mass	  72 
dynamics,	  ageing	  markers	  and	  lifespan	  of	  individuals	  followed	  over	  >	  4	  years	  of	  treatment.	  73 
	  74 
Material	  &	  Methods	  75 
As	  explained	  in	  details	  in	  Stier	  et	  al.	  (2014),	  60	  captive	  zebra	  finches	  (32	  females	  and	  28	  males)	  76 
were	  randomly	  allocated	  to	  either	  a	  control	  group,	  or	  an	  experimental	  group	  treated	  with	  ~4	  mg.kg-­‐77 
1.day-­‐1	  of	  DNP	  from	  0.75	  to	  5.2	  years	  of	  age.	  DNP	  treatment	  was	  administrated	  through	  the	  drinking	  78 
water	  and	  did	  not	  result	  in	  any	  alteration	  of	  water	  intake	  (Stier	  et	  al.,	  2014).	  The	  DNP	  dose	  was	  chosen	  79 
as	  the	  lowest	  dose	  eliciting	  an	  increase	  of	  whole-­‐body	  metabolic	  rate	  (Stier	  et	  al.,	  2014).	  Individuals	  80 
were	  followed	  longitudinally	  over	  the	  course	  of	  their	   life.	  Specifically,	  we	  measured	  body	  mass	  and	  81 
collected	  blood	  samples	  at	  11,	  14,	  24,	  34	  and	  58	  months	  of	  age.	  We	  estimated	  average	  metabolic	  rate	  82 
at	  12	  and	  24	  months	  of	  age	  as	  overnight	  VO2	  (see	  Stier	  et	  al.	  (2014)	  for	  details),	  while	  also	  recording	  83 
fasting	  body	  mass	   loss	  during	  the	  metabolic	  measurement	  (~10	  hours)	  normalized	  to	  24	  hours	   (i.e.	  84 
expressed	  in	  g.day-­‐1).	  We	  assessed	  vertical	  flight	  speed	  at	  12.5	  and	  25	  months	  of	  age	  following	  Reichert	  85 
et	  al.	  (2015)	  as	  an	  indicator	  of	  physical	  performance	  and	  used	  its	  decline	  with	  age	  as	  a	  biomarker	  of	  86 
ageing.	  We	  measured	   two	  biomarkers	  of	  ageing	   from	  blood	  samples.	  First,	  we	  measured	  oxidative	  87 
damage	  as	  plasma	   reactive	  oxygen	  metabolites	   (ROMs)	   (see	  Stier	  et	  al.	   (2014)	   for	  details).	   Indeed,	  88 
oxidative	  damage	  levels	  in	  the	  blood	  have	  been	  shown	  to	  increase	  with	  age,	  including	  in	  captive	  zebra	  89 
finches	  (Marasco	  et	  al.,	  2017),	  and	  high	  levels	  of	  plasma	  ROMs	  have	  been	  associated	  with	  increased	  90 
mortality	   risk	   in	  humans	   (Schöttker	  et	  al.,	  2015).	  Second,	  we	  measured	  relative	   telomere	   length	  of	  91 
blood	  cells	  using	  qPCR	  (see	  Reichert	  et	  al.	  (2014)	  for	  details).	  Indeed,	  telomeres	  usually	  shorten	  with	  92 
age,	  and	  short	   telomeres	  have	  been	  shown	  to	  predict	   increased	  mortality	   risk,	   including	   in	  captive	  93 
zebra	  finches	  (Heidinger	  et	  al.,	  2012).	  	  	  94 
Control	  and	  DNP-­‐treated	  birds	  did	  not	  statistically	  differ	  before	  the	  start	  of	  the	  treatment	  in	  95 
terms	  of	  body	  mass,	  metabolic	  rate	  or	  oxidative	  damage	  (see	  Stier	  et	  al.	  (2014)	  for	  details).	  Statistical	  96 
analyses	  were	  conducted	  using	  SPSS	  20.0.	  Metabolic	  rate,	  body	  mass,	  fasting	  body	  mass	  loss,	  ROMs	  97 
and	  telomere	  length	  were	  analyzed	  using	  general	  estimating	  equations	  (GEEs)	  with	  bird	  identity	  as	  a	  98 
random	  factor,	  and	  DNP	  treatment,	  Age	  and	  Sex	  as	  fixed	  factors	  (see	  details	   in	  Table	  2).	  Additional	  99 
covariates	  were	  added	  to	  specific	  models,	  such	  as	  body	  mass	  for	  the	  metabolic	  rate	  model	  and	  pre-­‐100 
treatment	  telomere	  length	  for	  the	  telomere	  model	  (see	  details	  in	  Table	  2).	  Survival	  was	  analyzed	  using	  101 
a	  Cox	  regression	  with	  DNP	  treatment	  as	  fixed	  factor,	  with	  20	  individuals	  still	  alive	  at	  the	  end	  of	  the	  102 
study	  (i.e.	  14	  control	  vs.	  6	  DNP)	  being	  censored.	  103 
	  104 
Results	  and	  Discussion	  105 
Chronic	   DNP	   treatment	   induced	   a	   moderate	   increase	   in	   energy	   expenditure	   that	   was	  106 
consistent	  over	  time	  (ca.	  +11%	  compared	  to	  control	  group,	  Fig.	  1A,	  Table	  2A),	  confirming	  that	  our	  DNP	  107 
dose	  induced	  a	  temporally	  stable	  mild	  uncoupling.	  However,	  DNP	  did	  not	  significantly	  influence	  the	  108 
expected	  slight	  increase	  in	  body	  mass	  observed	  with	  age	  (Fig.	  1B,	  Table	  2B),	  but	  it	  increased	  body	  mass	  109 
loss	  during	  fasting	  (Fig.	  1C,	  Table	  2C),	  which	  is	  in	  line	  with	  its	  effect	  on	  metabolic	  rate.	  DNP	  did	  not	  110 
appear	  to	  protect	  birds	  from	  the	  degradation	  of	  their	   locomotor	  performances	  with	  increasing	  age,	  111 
since	  the	  average	  flight	  speed	  decreased	  similarly	  in	  both	  control	  and	  DNP-­‐treated	  birds	  between	  12.5	  112 
and	  25	  months	  of	  age	  (Fig.	  1D,	  Table	  2D).	  	  113 
Ageing	  is	  a	  multifactorial	  process	  among	  which	  mitochondrial	  dysfunction,	  the	  accumulation	  114 
of	  oxidative	  damage	  and	  the	  shortening	  of	  telomeres	  are	  suggested	  to	  play	  a	  role	  (López-­‐Otín	  et	  al.,	  115 
2013).	  DNP	  did	  not	  significantly	  prevent	  the	  age-­‐related	   increase	   in	  oxidative	  damage	   levels	  over	  a	  116 
period	  of	  ca.	  4	  years	  (Fig.	  1E,	  Table	  2E),	  confirming	  our	  previous	  results	  in	  early	  adulthood	  (Stier	  et	  al.,	  117 
2014).	  Telomere	   length	  and	  shortening	  rate	  are	  thought	  to	  play	  a	  causal	  role	   in	  the	  ageing	  process	  118 
(Muñoz-­‐Lorente	  et	  al.,	  2019).	  Yet,	  we	  found	  no	  significant	  effect	  of	  chronic	  DNP	  exposure	  on	  telomere	  119 
length	   or	   the	   age-­‐related	   telomere	   shortening	   (Fig.	   1F,	   Table	   2F),	   suggesting	   no	   protective	   or	  120 
detrimental	   effects	   of	   mild	   mitochondrial	   uncoupling	   on	   cellular	   ageing	   rate.	   Finally,	   our	   study	  121 
highlights	  an	  overall	  detrimental	  effect	  of	  chronic	  DNP	  treatment	  on	  lifespan	  (median	  lifespan:	  DNP	  =	  122 
1420	  days,	  Control	  =	  1803	  days;	  B	  =	  -­‐0.66	  ±	  0.32,	  Wald	  χ2	  =	  4.17,	  p	  =	  0.041,	  Fig.	  1G),	  a	  result	  in	  complete	  123 
contradiction	  with	  previous	  experiments	  in	  other	  eukaryotic	  models	  (Table	  1).	  124 
This	  disparity	  with	  previously	  published	  results	  could	  hypothetically	  be	  linked	  to	  specificities	  125 
in	  avian	  physiology	  and	   life-­‐history.	   For	   instance,	  birds	  differ	   from	  mammals	   in	   terms	  of	   longevity,	  126 
being	  typically	  long-­‐lived	  for	  their	  body	  size	  (Holmes	  et	  al.,	  2001).	  Zebra	  finches	  have	  a	  typical	  median	  127 
lifespan	  of	  approximately	  3-­‐5	  years	  (e.g.	  ~3	  years	  in	  Marasco	  et	  al.	  2017;	  ~4	  years	  in	  Briga	  et	  al.	  2019;	  128 
~5	  years	  in	  the	  present	  study	  for	  control	  birds),	  being	  therefore	  longer-­‐lived	  than	  laboratory	  mice	  (~	  2	  129 
years	   in	  Caldeira	  da	  Silva	  et	  al.,	  2008).	  Humans	  and	  birds	  being	   long-­‐lived	  for	  their	  body	  size,	  some	  130 
authors	   suggested	   that	  birds	   could	  be	  better	  models	   to	  understand	  human	  ageing	   than	   traditional	  131 
short-­‐lived	  rodents	  (Holmes	  and	  Ottinger,	  2003).	  	  On	  another	  note,	  we	  have	  previously	  shown	  that	  the	  132 
sensitivity	  of	  in	  vitro	  mitochondrial	  ROS	  was	  lower	  in	  zebra	  finch	  than	  in	  laboratory	  mouse	  (Stier	  et	  al.,	  133 
2014),	  which	  could	  contribute	  to	  explain	  the	  difference	  between	  results	  on	  mice	  (Caldeira	  da	  Silva	  et	  134 
al.,	  2008)	  and	  zebra	  finches	  (this	  study).	  Yet,	  our	  results	  suggest	  that	  deleterious	  effects	  of	  chronic	  DNP	  135 
intake	  could	  occur	  and	  calls	  for	  further	  studies	  using	   long-­‐term	  DNP	  treatment	   in	  other	  endotherm	  136 
models	  that	  do	  not	  necessarily	  display	  age-­‐related	  obesity.	  	  137 
Our	  study	  highlights	  that,	  even	  at	  a	  moderate	  dose	  (i.e.	  increasing	  metabolic	  rate	  by	  only	  ca.	  138 
11%),	  a	  chronic	  DNP	  treatment	  can	  shorten	  lifespan.	  DNP	  promotes	  proton	  flow	  not	  only	  across	  the	  139 
mitochondrial	  membrane,	  but	  across	  the	  plasma	  membrane	  as	  well	  (Jastroch	  et	  al.,	  2014).	  This	  could	  140 
be	  one	  key	  element	  explaining	  the	  negative	  impact	  of	  DNP	  on	  lifespan,	  but	  could	  potentially	  be	  solved	  141 
using	   next	   generation	   uncouplers	   (e.g.	   BAM15)	   being	   specific	   to	   the	   mitochondrial	   membrane	  142 
(Jastroch	  et	  al.,	  2014).	  Further	  studies	  investigating	  the	  molecular	  and	  physiological	  pathways	  by	  which	  143 
DNP	  shortens	  lifespan	  in	  zebra	  finches	  would	  be	  useful	  to	  enable	  targeted	  investigations	  of	  sublethal	  144 
deleterious	  effects	  in	  other	  animal	  models	  and	  potentially	  in	  humans.	  The	  present	  study	  should	  be	  a	  145 
potential	  warning	  signal	  for	  current	  illegal	  DNP	  users,	  and	  raise	  questions	  for	  scientists	  investigating	  146 
DNP	  use	  as	  a	  medicine.	  	  147 
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Fig.	  1:	  Zebra	  finches	  chronically	  treated	  with	  2,4-­‐Dinitrophenol	  (DNP)	  in	  their	  drinking	  water	  present:	  249 
(A)	  a	  mild	  increase	  in	  metabolic	  rate,	  (B)	  no	  changes	  in	  the	  mild	  increase	  in	  body	  mass	  with	  age,	  (C)	  a	  250 
higher	   body	   mass	   loss	   during	   fasting,	   (D)	   no	   change	   in	   the	   decrease	   of	   locomotor	   (flight)	  251 
performances	  with	  age,	  (E)	  no	  change	  in	  the	  age-­‐related	  increase	  in	  oxidative	  damage,	  or	  (F)	  the	  age-­‐252 
related	   shortening	   of	   telomeres.	   Yet,	   DNP	   significantly	   reduces	   lifespan	   (G).	   Control	   birds	   are	  253 
indicated	  in	  blue	  and	  DNP	  birds	  in	  red,	  means	  are	  plotted	  ±	  SE,	  p-­‐values	  and	  N	  are	  presented	  within	  254 
each	   panel	   and	   letters	   indicate	   significant	   differences	   according	   to	   sequential	   Bonferroni	   post-­‐hoc	  255 
tests	  for	  GEE	  models.	  256 
	   	  257 
Table	  1:	  Summary	  of	  studies	  on	  the	  effects	  of	  chronic	  2,4-­‐Dinitrophenol	  (DNP)	  treatment,	  from	  yeast	  258 
to	  humans.	  ()	  indicate	  observational	  data	  in	  humans	  based	  on	  early	  reports	  (~1930’s)	  and	  poisoning	  259 
incidents,	  ?:	  not	  tested,	  =:	  no	  significant	  change,	  ↓:	  decrease	  and	  ↑:	  increase.	  260 
	  261 
	  262 
	   Human	   Mouse	   Zebra	  finch	   Frog	  tadpole	   Drosophila	   Yeast	  









Body	  mass	   (↓)	   ↓	   =	   =	   ?	   ?	  
Metabolic	  
rate	  
(↑)	   ↑	   ↑	   ↑	   =	   ↑	  
Oxidative	  
stress	  
?	   ↓	   =	   ↓	   ?	   ↓	  
Lifespan	   ?	   ↑	   ↓	   ?	   ↑	   ↑	  
Reference	   Harris	  and	  
Cocoran	  1995	  
Caldeira	  da	  Silva	  
et	  al.	  2008	  
Stier	  et	  al.	  2014;	  
this	  study	  







Table	  2:	  Results	  of	  GEE	  models	   testing	  the	  effects	  of	  age,	  DNP	  treatment	  and	  sex	  on	  (A)	  average	  264 
metabolic	  rate,	  (B)	  body	  mass,	  (C)	  fasting	  body	  mass	  loss,	  (D)	  flight	  performance,	  (E)	  plasma	  ROMs	  265 
levels	  and	  (F)	  blood	  cell	  relative	  telomere	  length	  266 
A.   Metabolic	  rate	  (average	  VO2)	  
	  
Fixed	  effects:	   Estimate	   Std.	  Error	   Wald	  χ2	   p	  
Intercept	   1.36	   0.28	   	   	  
Age	  (24mo)	   0.38	   0.07	   43.38	   <	  0.001	  
Treatment	  (DNP)	   0.21	   0.07	   12.77	   <	  0.001	  
Age*Treatment	   	   	   	   (0.97)	  
Sex	  (F)	   0.05	   0.06	   0.81	   0.37	  
Body	  mass	   0.04	   0.02	   5.69	   0.017	  
	  
B.   Body	  mass	  
	  
Fixed	  effects:	   Estimate	   Std.	  Error	   Wald	  	  χ2	   p	  
Intercept	   16.09	   0.59	   	   	  
Age	  (11mo)	   -­‐1.44	   0.43	   38.79	   <	  0.001	  
Treatment	  (DNP)	   -­‐0.01	   0.45	   12.77	   0.99	  
Age*Treatment	   	   	   	   (0.70)	  
Sex	  (F)	   0.33	   0.45	   0.81	   0.46	  
	  
C.   Fasting	  body	  mass	  loss	  
	  
Fixed	  effects:	   Estimate	   Std.	  Error	   Wald	  	  χ2	   p	  
Intercept	   2.22	   0.59	   	   	  
Age	  (24mo)	   0.19	   0.08	   5.44	   0.020	  
Treatment	  (DNP)	   0.19	   0.09	   4.20	   0.040	  
Age*Treatment	   	   	   	   (0.37)	  
Sex	  (F)	   0.10	   0.09	   1.33	   0.25	  
	  
D.   Flight	  performance	  
	  
Fixed	  effects:	   Estimate	   Std.	  Error	   Wald	  	  χ2	   p	  
Intercept	   2.22	   0.59	   	   	  
Age	  (25mo)	   -­‐0.28	   0.05	   28.82	   <	  0.001	  
Treatment	  (DNP)	   0.05	   0.10	   4.20	   0.63	  
Age*Treatment	   	   	   	   (0.80)	  
Sex	  (F)	   0.11	   0.10	   1.25	   0.26	  
	  
E.   Plasma	  ROMs	   	   	   	   	  
	   	   	   	   	  
Fixed	  effects:	   Estimate	   Std.	  Error	   Wald	  	  χ2	   p	  
Intercept	   5.54	   0.55	   	   	  
Age	  (24mo)	   1.38	   0.55	   74.86	   <	  0.001	  
Treatment	  (DNP)	   -­‐0.07	   0.25	   0.08	   0.78	  
Age*Treatment	   	   	   	   (0.89)	  
Sex	  (F)	   0.81	   0.25	   10.77	   0.001	  
	  
F.   Telomere	  length	  	   	   	   	   	  
	   	   	   	   	  
Fixed	  effects:	   Estimate	   Std.	  Error	   Wald	  	  χ2	   p	  
Intercept	   -­‐0.25	   0.19	   	   	  
Age	  (34mo)	   -­‐0.66	   0.12	   89.09	   <	  0.001	  
Treatment	  (DNP)	   0.09	   0.10	   0.81	   0.37	  
Age*Treatment	   	   	   	   (0.94)	  
Sex	  (F)	   0.21	   0.10	   4.09	   0.043	  
Initial	  telomere	  length	   0.42	   0.10	   18.58	   <	  0.001	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